Do you want to read an article? Please log in or register.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Breast Cancer
Related content
Breast Cancer
Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis
Adv Ther
Earla JR, Kurian AW, Kponee-Shovein K, Mahendran M, Song Y, Hua Q, Hilts A, Sun Y, Hirshfield KM, Robson M, Mejia JA
doi: 10.1007/s12325-024-03074-7
Breast Cancer
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers
Clin Cancer Res
Rios-Hoyo A, Xiong K, Dai J, Yau C, Marczyk M, Garcia-Milian R, Wolf DM, Huppert LA, Nanda R, Hirst GL, Cobain EF, van 't Veer LJ, Esserman LJ, Pusztai L
doi: 10.1158/1078-0432.CCR-24-1553
ASCO 2024
Breast Cancer
NATALEE: Ribociclib plus NSAI is effective and tolerable in patients with high-risk node-negative HR-positive, HER2-negative early breast cancer
Breast Cancer
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer
JAMA Oncol
O'Regan RM, Zhang Y, Fleming GF, Francis PA, Kammler R, Viale G, Dell'Orto P, Lang I, Bellet M, Bonnefoi HR, Tondini C, Villa F, Bernardo A, Ciruelos EM, Neven P, Karlsson P, Müller B, Jochum W, Zaman K, Martino S, Geyer CE Jr, Jerzak KJ, Davidson NE, Coleman RE, Ingle JN, van Mackelenbergh MT, Loi S, Colleoni M, Schnabel CA, Treuner K, Regan MM
doi: 10.1001/jamaoncol.2024.3044
Breast Cancer
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer
J Clin Oncol
Conforti F, Nekljudova V, Sala I, Ascari R, Solbach C, Untch M, Denkert C, Bagnardi V, Pala L, Fasching PA, Schneeweiss A, Lück HJ, Pagan E, De Pas T, van Mackelenbergh M, Huober J, Müller V, Link T, Karn T, Reinisch M, Marmé F, Bjelic-Radisic V, Schem C, Hartkopf A, Stickeler E, Hanusch C, Blohmer JU, Fehm T, Rhiem K, Holtschmidt J, Gelber RD, Loibl S
doi: 10.1200/JCO-24-01360
SABCS 2024
Breast Cancer
OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer
Gynecologic Cancer
LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer
J Clin Oncol
Ramirez PT, Robledo KP, Frumovitz M, Pareja R, Ribeiro R, Lopez A, Yan X, Isla D, Moretti R, Bernardini MQ, Gebski V, Asher R, Behan V, Coleman RL, Obermair A
doi: 10.1200/JCO.23.02335
ASCO 2024
Breast Cancer
SACI-IO HR+: Adding pembrolizumab to sacituzumab govitecan shows numerical PFS improvement in HR-positive, HER2-negative breast cancer
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
★ 2
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lancet
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S, KEYNOTE-671 Investigators
doi: 10.1016/S0140-6736(24)01756-2